

## State of Maine Procurement Justification Form

This form must accompany all contract requests and sole source requisitions (RQS) over \$5,000 submitted to the Division of Procurement Services.

INSTRUCTIONS: Please provide the requested information in the white spaces below.

### PART I: OVERVIEW

Department Office/Division/Program:		DHHS/Maine CDC		
Department Contract Administrator or Grant Coordinator:		Chris Moiles/Jennifer Levesque		
(If applicable) Department Reference #:		CD0-21-5434		
Amount: (Contract/Amendment/Grant)	\$ 250,000.00	Advantage CT / RQS #:	CT 10A 20210226000000002345	
CONTRACT	Proposed Start Date:	1/20/2021	Proposed End Date:	1/19/2022
AMENDMENT	Original Start Date:		Effective Date:	
	Previous End Date:		New End Date:	
GRANT	Project Start Date:		Grant Start Date:	
	Project End Date:		Grant End Date:	
Vendor/Provider/Grantee Name, City, State:		The Jackson Laboratory		
Brief Description of Goods/Services/Grant:		Supplemental COVID-19 Laboratory operations and testing services		

### PART II: JUSTIFICATION FOR VENDOR SELECTION

Mark an "X" before the justification(s) that applies to this request. (Check all that apply.)

<input type="checkbox"/>	A. Competitive Process	<input type="checkbox"/>	G. Grant
<input type="checkbox"/>	B. Amendment	<input type="checkbox"/>	H. State Statute/Agency Directed
<input type="checkbox"/>	C. Single Source/Unique Vendor	<input type="checkbox"/>	I. Federal Agency Directed
<input type="checkbox"/>	D. Proprietary/Copyright/Patents	<input type="checkbox"/>	J. Willing and Qualified
<input checked="" type="checkbox"/>	E. Emergency	<input type="checkbox"/>	K. Client Choice
<input type="checkbox"/>	F. University Cooperative Project	<input checked="" type="checkbox"/>	L. Other Authorization – COVID-19

### PART III: SUPPLEMENTAL INFORMATION

Please respond to ALL of the following:

**1. Provide a more detailed description and explain the need for the goods, services or grant to supplement the response in Part I.**

First identified in December 2019, Coronavirus Disease 2019 (COVID-19) is a mild to severe respiratory disease with a significant mortality rate. The etiological agent of COVID-19, severe acute respiratory syndrome-related coronavirus (SARS-CoV-2), appears to have originated in Wuhan City, Hubei Province, China and has since rapidly spread globally. As of January 10, 2021, this includes 90.2 million confirmed cases and 1.2 million deaths with 19% of the deaths occurring in the United States. As this outbreak continues to spread, action is required to quickly catalog viral diversity to understand the evolution of the epidemic, transmission dynamics, evolutionary rates, and provide real-time surveillance of new and expanding viral mutations.

## State of Maine Procurement Justification Form

### PART III: SUPPLEMENTAL INFORMATION

This information can be used by public health officials while monitoring and tracking to mount a well informed and more robust response to SARS-CoV-2 within their areas of operation (1). Recently, two variants of concern (VOCs) have emerged independently, detected by on-going surveillance efforts in the United Kingdom and South Africa. These two VOCs (B.1.1.7 and B.1.351), show strong epidemiological evidence of increased transmissibility and carry mutations shown to weaken neutralization by some human sera. One VOC has now been detected in the United States and aggressive monitoring for new occurrences is of critical importance.

The purpose of this Agreement is to supplement COVID-19 testing performed by the Maine Health and Environmental Testing Laboratory (HETL). The addition of the Lab Services to the HETL's current capacity should substantially augment the Department's capacity to develop a comprehensive understanding of the evolution and transmission of SARS-CoV-2 in near real time.

The Provider shall, over the next nine (9) months, develop a working collaboration with the Maine Center for Disease Control and Prevention (ME-CDC) to establish a protocol for the transfer nucleic acid from COVID-19 positive samples, to Provider in Bar Harbor for genomic analysis.

#### 2. Provide a brief justification for the selected vendor to supplement the response in Part II.

Over the past 9 months the Jackson Laboratory (Provider) has developed a working collaboration with the Maine Center for Disease Control and Prevention (ME-CDC) to establish a protocol for the transfer nucleic acid from COVID-19 positive samples to Provider in Bar Harbor for genomic analysis. Provider currently has a working MTAs in place and developed a workflow for the weekly transfer of samples from the ME-CDC to Provider. As of January 10, 2021, the Provider has sequenced and deposited 368 samples placing the state as the 4th most surveyed state in the US by proportion of cases sequence (1.5%).

#### 3. Explain how the negotiated costs or rates are fair and reasonable; or how the funding was allocated to grantee.

The Department looked at available companies to provide these services; this organization was the only one that could support the Department's need. As such, the Department reviewed the pricing, which was deemed acceptable in light of the Governor's Civil State of Emergency. This work is surveillance only and cannot be charged to patients; much like most of the work conducted at HETL. The included budget (Appendix B) has a breakdown of supplies, equipment, staff, and mandatory fees. HETL is not buying a service on a per sample basis but providing Jackson labs federal funding per grant requirements to meet these grant requirements. Jackson Labs is including the cost of per sample for transparency purposes.

#### 4. Describe the plan for future competition for the goods or services.

The department does not intend to RFP this service at this time.

### PART IV: APPROVALS

<b>Signature of requesting Department's Commissioner (or designee):</b>	<i>By signing below, I signify that I approve of this procurement request.</i>		
	<small>DocuSigned by:</small>		
	<i>Benjamin Mann</i>		
<b>Printed Name:</b>	<small>2870DA6E0E76471...</small> Benjamin Mann	<b>Date:</b>	Mar-15-2021
<b>Signature of DAFS Procurement Official:</b>	<small>DocuSigned by:</small>		
	<i>Kathy Paquette</i>		
<b>Printed Name:</b>	<small>41C2BA36FAF44CD...</small> Kathy Paquette	<b>Date:</b>	4/2/2021